NASDAQ:LGVN Longeveron Q3 2026 Earnings Report $2.37 -0.14 (-5.58%) As of 01:59 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Longeveron EPS ResultsActual EPSN/AConsensus EPS -$1.95Beat/MissN/AOne Year Ago EPSN/ALongeveron Revenue ResultsActual RevenueN/AExpected Revenue$0.56 millionBeat/MissN/AYoY Revenue GrowthN/ALongeveron Announcement DetailsQuarterQ3 2026Date11/3/2026TimeAfter Market ClosesConference Call DateTuesday, November 3, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Longeveron Earnings HeadlinesLongeveron average analyst price target decreased by 23.41% to $42.97October 2, 2026 | msn.comFinancial Contrast: uniQure (NASDAQ:QURE) and Longeveron (NASDAQ:LGVN)October 2, 2026 | americanbankingnews.comThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and America's $40 trillion national debt to a potential surge in gold prices, with some forecasts pointing to $10,000 or even $20,000 gold. Dr. David Eifrig, a 40-year market veteran and former Goldman Sachs Vice President, says an unusual plan involving Trump and two other top officials could fuel the biggest gold bull run in decades. Eifrig has shared his top gold pick tied to this developing story.October 6 at 1:00 AM | Stansberry Research (Ad)Comparing Longeveron (NASDAQ:LGVN) & ProQR Therapeutics (NASDAQ:PRQR)October 1, 2026 | americanbankingnews.comLongeveron to Participate in Three Longevity/Aging Investment ConferencesSeptember 30, 2026 | globenewswire.comFinancial Contrast: Sera Prognostics (NASDAQ:SERA) and Longeveron (NASDAQ:LGVN)September 30, 2026 | americanbankingnews.comSee More Longeveron Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Longeveron? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Longeveron and other key companies, straight to your email. Email Address About LongeveronLongeveron (NASDAQ:LGVN) (NASDAQ: LGVN) is a clinical-stage biotechnology company developing regenerative medicines intended to address serious and life-threatening conditions. Its lead product candidate, Lomecel-B, is an allogeneic medicinal signaling cell therapy derived from the bone marrow of healthy adult donors. The company is investigating the therapy for its potential to promote tissue repair, modulate inflammation and support blood-vessel formation. Lomecel-B is being evaluated in clinical programs targeting hypoplastic left heart syndrome, an uncommon and severe congenital heart condition, as well as aging-related frailty and Alzheimer’s disease. Longeveron’s research focuses on the broader use of cell-based therapies in conditions for which existing treatment options are limited. Founded in 2014 and headquartered in Miami, Florida, Longeveron conducts research and clinical development activities in the United States and has pursued programs involving international collaborators and clinical sites. The company is led by Chief Executive Officer Wa’el Hashad.View Longeveron ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AI Chip Demand Gives Linde a New Growth Catalyst3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street Divided Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
